Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 12 , ISSUE 4 ( December, 2008 ) > List of Articles

Educational Forum

Biological agents targeting beyond TNF-alpha

Annil Mahajan, Rashmi Sharma, Chaman Lal Sharma

Citation Information : Mahajan A, Sharma R, Sharma CL. Biological agents targeting beyond TNF-alpha. Indian J Crit Care Med 2008; 12 (4):181-189.

DOI: 10.4103/0972-5229.45079

License: CC BY-ND 3.0

Published Online: 01-01-2012

Copyright Statement:  Copyright © 2008; The Author(s).


Abstract

Biological agents represent an important addition to the therapies for immuno-inflammatory conditions and have a great impact on the disease course and quality of life of these patients. However, recent reports of serious infections like tuberculosis, demyelinating and neurodegenerative diseases, pancytopenia, cardiovascular diseases, etc. after anti-TNF therapy raised questions on their safety. Hence, focus is shifted towards drugs targeting cytokine checkpoints in the inflammatory cascades beyond TNF-a. Existing therapeutic targets include the biological agents acting as antagonists of various inflammatory cytokines (Anakinra, Tocilizumab, Atlizumab) and modulators of CD80 or CD86-CD28 co-stimulatory signal (Abatacept), CD2 receptors on T-cells (Alefacept), CD11a, subunit of leukocyte function-associated antigen 1 (Efalizumab), vitronectin receptor and CD20 antigen on pre-B, immature and mature B cells (Rituximab). With the introduction of these novel molecules the future for immunomodulatory intervention in rheumatology, asthma, crohn′s disease, septic shock etc. looks very promising. These novel therapeutic agents could truly give a new hope to the clinician to modify the disease and achieve tangible improvements in the lives of the patients.

PDF Share
  1. From laboratory to clinic: Rationale for biologic therapy. Dermatol Clin 2004;22:371-7.
  2. Biologic therapy in psoriasis. Indian J Dermatol Venereol Leprol 2006;72:256-65.
  3. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-a therapy. Rheumatology 2003;42:617-21.
  4. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:31-9.
  5. Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo 2006;58:31-8.
  6. Future prospects for anti-cytokine treatment. Ann Rheum Dis 2000;59:i119-22.
  7. Available from: http://www.nic.sav.sk/logos/books/scientific/node32.html. [last assessed on 2006 Dec 10].
  8. imgenex.com/CytokineChemokine.php - 87k. [last assessed on 2006 Dec 10].
  9. Biologic therapies in Rheumatoid arthritis. Curr Rheu Rep 1999,1:157-63.
  10. A novel therapeutic approach in rheumatoid arthritis. Ind J Pharmacol 2005;36:265-6.
  11. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: Clinicopathological study of five patients. Br J Dermatol 2005;153:417-23.
  12. Non-tumor necrosis factor biological therapies for rheumatoid arthritis. Am J Rheumatol 2005;8:77-83.
  13. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9:S136-43.
  14. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760-2.
  15. Full guidance: Anakinra for rheumatoid arthritis. Technology appraisal Nov 2003. Available from: http://www.nice.org.uk/pdf/Tao72 guidance pdf. [last assessed on 2004 Jun 24].
  16. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:574-8.
  17. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838-46.
  18. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Paediatr 2006;95:246-9.
  19. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther 2006;23:208-17.
  20. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor-a inhibition. N Engl J Med 2005;353:1114-23.
  21. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
  22. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
  23. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 2003;49:816-25.
  24. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;21:2004-13.
  25. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized control trial. JAMA 2003;23:3073-80.
  26. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trials. J Am Acad Dermatol 2005;52:425-33.
  27. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8.
  28. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Indian J Dermatol Venereol Leprol 2006;72:173-4.
  29. Available from: http://www.leaddiscovery.co.uk/dailyupdates_alert_MArch_1.html. [last assessed on 2006 Aug 16].
  30. Monoclonal antibodies: Targeted therapy. Indian J Pharmacol 2006;38:390-6.
  31. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol (Oxford) 2001;40:205-11.
  32. Treatment of severe rheumatoid arthritis by anti- interleukin-6 monoclonal antibody. J Rheumatol 1993;20:259-62.
  33. Toxicity, Pharmacokinetics and dose-finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis phase I/II clinical study. J Rheumatol 2003;30:1426-35.
  34. Emerging biologic therapies in rheumatoid arthritis: Cell targets and cytokines. Curr Opin Rheumatol 2005;2:38-43.
  35. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005;28:231-8.
  36. Biological therapies for rheumatoid arthritis: Beyond TNF-[alpha] blockade. Aplar J Rheumatol 2006;9:200-5.
  37. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63:321-9.
  38. Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum 2005;52:2686-92.
  39. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003;19:503-14.
  40. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Resp Critical care Med 2007; 176:1062-71.
  41. Therapeutic dosing with anti interleukin-13 monoclonal antibody inhibits Asthma progression in mice. J Pharm Exp Ther 2005;313:8-15.
  42. Colin R R, Christopher, Seamas D. Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Critical Care Med 2002;30: 2335-7.
  43. Anticytokine Therapy May Be Effective in Active Crohn′s Disease. www.medscap.com, assessed on 24-12-2008.
  44. Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome. BioMedical Press, Augusta, GA, ETATS-UNIS (1994) (Revue) www.cat.inist.fr. Assessed on 24-12-2008.
  45. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 203-7.
  46. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-76.
  47. The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
  48. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 2004; 63: 1393-8.
  49. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19: 641-4.
  50. Adipocytokines in synovial fluid. JAMA 2003; 290: 1709-10.
  51. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-95.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.